Seismic Pharmaceutical Holdings, LLC acquires the cardiovascular assets and will pay Windtree 20% of any milestone payments, royalty payments or similar economic interests (including all global commercial net revenues)

Windtree would receive a payment of $700,000 from Seismic Pharmaceutical Holdings contingent on a financing round resulting in gross cash proceeds of at least $10,000,000

Additionally, Windtree transfers certain cardiovascular development payables to Seismic Pharmaceutical Holdings

WARRINGTON, Pa., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") (OTCID: WINT), a diversified company with several divisions and focused on becoming a revenue generating company, announced that it has signed an agreement for the sale of its cardiovascular drug candidates to Seismic Pharmaceutical Holdings, LLC. ("SPH"), a private investment group based in North Carolina, USA.

Windtree is entitled to 20% of any future proceeds received by SPH. This would include global commercial net revenue in acute heart failure (AHF) if approved by regulatory authorities. There were 2.1 and 2.7 million AHF hospital admissions in 2022 in the US and EU respectively. Windtree believes that the AHF global drug market value is in the ...